Compare MBIN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | STOK |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 735 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | MBIN | STOK |
|---|---|---|
| Price | $46.64 | $29.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $43.67 | $39.20 |
| AVG Volume (30 Days) | 116.5K | ★ 448.5K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $31.76 | N/A |
| Revenue Next Year | $3.73 | $77.49 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $28.75 | $9.09 |
| 52 Week High | $50.26 | $40.22 |
| Indicator | MBIN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 35.82 |
| Support Level | $45.12 | $25.21 |
| Resistance Level | $48.50 | $35.11 |
| Average True Range (ATR) | 1.32 | 1.65 |
| MACD | -0.12 | -0.29 |
| Stochastic Oscillator | 74.36 | 25.28 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.